Robert L. Van Nostrand - Aug 11, 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Aug 11, 2022
Transactions value $
-$1,334,475
Form type
4
Date filed
8/12/2022, 06:09 PM
Previous filing
Jul 5, 2022
Next filing
Oct 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $249K +20K +221.17% $12.45 29K Aug 11, 2022 Direct
transaction ITCI Common Stock Options Exercise $131K +10K +34.43% $13.05 39K Aug 11, 2022 Direct
transaction ITCI Common Stock Sale -$1.63M -28.5K -73% $57.15 10.5K Aug 11, 2022 Direct F1
transaction ITCI Common Stock Sale -$85.2K -1.5K -14.23% $56.80 9.04K Aug 11, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -20K -100% $0.00* 0 Aug 11, 2022 Common Stock 20K $12.45 Direct F3
transaction ITCI Stock Option (right to buy) Options Exercise $0 -10K -50% $0.00 10K Aug 11, 2022 Common Stock 10K $13.05 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.775 to $56.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 All shares underlying this option have vested.